Deep Dive Into Edwards Lifesciences Stock: Analyst Perspectives (14 Ratings)
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse perspectives on Edwards Lifesciences (NYSE:EW), with 14 ratings in the last three months. The average 12-month price target is now $78.5, down 11.62% from the previous $88.82. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Edwards Lifesciences, known for its medical devices for structural heart disease, has shown a revenue growth of 12.27% and strong financial health with high net margin and ROE. However, its revenue growth lags behind industry peers.
December 22, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Edwards Lifesciences has received varied analyst ratings with a downward revision in the average price target to $78.5. The company's strong financials may counterbalance the negative sentiment from the reduced price targets.
The diverse analyst ratings and the reduction in the average price target suggest uncertainty, which could lead to a neutral short-term impact on the stock price. However, the company's strong financial performance, including high net margin and ROE, may provide a counterbalancing effect, supporting the stock price despite the lowered targets.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100